RCS - ReNeuron Group plc - CTX-iPSC platform data shows commerical potential

ReNeuronAnnouncement

19/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211119:nRSS8998Sa&default-theme=true

RNS Number : 8998S  ReNeuron Group plc  19 November 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

 

New CTX-iPSC platform data shows potential in Peripheral Nerve Repair

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, announces that new data relating to its CTX-derived
induced Pluripotent Stem Cell ("CTX-iPSC") platform has been presented this
week, showing their commercial potential for the development of mass-scale
therapeutics for peripheral nerve repair.

 

The data has been presented at the 6th world congress of the Tissue
Engineering and Regenerative Medicine International Society (TERMIS2021), a
leading scientific conference taking place in Maastricht, Netherlands.

 

Ms Rebecca Powell from the University College London ('UCL') Centre for Nerve
Engineering presented new data showing for the first time that ReNeuron's
CTX-iPSCs can be differentiated to produce Schwann cells, a specific type of
support cell that promotes the survival and function of peripheral nerves and
importantly, when present in the appropriate three-dimensional configuration,
could promote the regrowth of nerve axons damaged by traumatic injury, thus
hopefully resulting in the regain of lost functions. The conditional
immortalisation cassette present in CTX-iPSCs also promotes a much higher
survival of mature Schwann cells.

 

The abstract from the conference can be found here:
https://insight.klinkhamergroup.com/termis2021/book/abstract/878
(https://linkprotect.cudasvc.com/url?a=https%3a%2f%2finsight.klinkhamergroup.com%2ftermis2021%2fbook%2fabstract%2f878&c=E,1,Fv4ShXUKraExGH2mzgbxfOdT1MmfOHp43bFfqsaj7xjErIbepBTam6Fmqw5y6-6Oi3xAsEo88vodlJ-DTOjdxWvaWr-YIZjbsTMRwiP_Ww-2Z-IH3w,,&typo=1)

 

Professor Stefano Pluchino, Chief Scientific Officer at ReNeuron, commented:
"These independently generated results are particularly encouraging as they
support the idea that ReNeuron's CTX-iPSCs, initially reprogrammed from a
proprietary, conditionally immortalised, well-characterised, clinical grade
neural stem cell line, may allow for the potential to scale production of 'off
the shelf' allogeneic tissue engineered therapeutics. This makes them a
feasible mass-scale solution for areas such as peripheral nerve repair."

 

Background

The Company has previously presented data demonstrating that its proprietary
human CTX neural stem cell line  can be successfully and rapidly reprogrammed
to a pluripotent, embryonic stem cell-like state enabling differentiation into
any cell type. In essence, this means that the Company is able to take its
neural stem cells back to being stem cells that can be made to develop into
any other type of cell in the body, including bone, nerve, muscle and skin.
Furthermore, CTX-iPSCs also hold the remarkable potential of permitting the
scalable manufacture of adult stem cells or tissue progenitor populations for
cell therapy.

 

ENDS

 

 ReNeuron                                                 www.reneuron.com/investors (http://www.reneuron.com/investors)
 Olav Hellebø, Chief Executive Officer                    Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)  +44 (0)20 7710 7600
 Ben Maddison, Stewart Wallace

 Allenby Capital Limited (Joint Broker)                   +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                 +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus, Alice Woodings                             +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique
stem cell technologies to develop 'off the shelf' stem cell treatments for
disease with significant unmet needs. The Company's lead cell therapy
candidate is in clinical development for the blindness-causing disease,
retinitis pigmentosa.

 

ReNeuron is also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that treat diseases of the central nervous
system and other disorders. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform to
make allogeneic tissue cells of choice; in-house programmes are currently
focused on treatments for blood cancers and diabetes.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZMMMZRZGMZZ